237 related articles for article (PubMed ID: 27894941)
1. One year of abaloparatide, a selective peptide activator of the PTH1 receptor, increased bone mass and strength in ovariectomized rats.
Varela A; Chouinard L; Lesage E; Guldberg R; Smith SY; Kostenuik PJ; Hattersley G
Bone; 2017 Feb; 95():143-150. PubMed ID: 27894941
[TBL] [Abstract][Full Text] [Related]
2. One Year of Abaloparatide, a Selective Activator of the PTH1 Receptor, Increased Bone Formation and Bone Mass in Osteopenic Ovariectomized Rats Without Increasing Bone Resorption.
Varela A; Chouinard L; Lesage E; Smith SY; Hattersley G
J Bone Miner Res; 2017 Jan; 32(1):24-33. PubMed ID: 27748532
[TBL] [Abstract][Full Text] [Related]
3. Six Weeks of Daily Abaloparatide Treatment Increased Vertebral and Femoral Bone Mineral Density, Microarchitecture and Strength in Ovariectomized Osteopenic Rats.
Bahar H; Gallacher K; Downall J; Nelson CA; Shomali M; Hattersley G
Calcif Tissue Int; 2016 Nov; 99(5):489-499. PubMed ID: 27395059
[TBL] [Abstract][Full Text] [Related]
4. Abaloparatide, a novel PTH receptor agonist, increased bone mass and strength in ovariectomized cynomolgus monkeys by increasing bone formation without increasing bone resorption.
Doyle N; Varela A; Haile S; Guldberg R; Kostenuik PJ; Ominsky MS; Smith SY; Hattersley G
Osteoporos Int; 2018 Mar; 29(3):685-697. PubMed ID: 29260289
[TBL] [Abstract][Full Text] [Related]
5. Abaloparatide increases bone mineral density and bone strength in ovariectomized rabbits with glucocorticoid-induced osteopenia.
Chandler H; Brooks DJ; Hattersley G; Bouxsein ML; Lanske B
Osteoporos Int; 2019 Aug; 30(8):1607-1616. PubMed ID: 31053927
[TBL] [Abstract][Full Text] [Related]
6. Abaloparatide improves cortical geometry and trabecular microarchitecture and increases vertebral and femoral neck strength in a rat model of male osteoporosis.
Besschetnova T; Brooks DJ; Hu D; Nagano K; Nustad J; Ominsky M; Mitlak B; Hattersley G; Bouxsein ML; Baron R; Lanske B
Bone; 2019 Jul; 124():148-157. PubMed ID: 31051317
[TBL] [Abstract][Full Text] [Related]
7. Biosynthetic human parathyroid hormone (1-34) effects on bone quality in aged ovariectomized rats.
Sato M; Zeng GQ; Turner CH
Endocrinology; 1997 Oct; 138(10):4330-7. PubMed ID: 9322947
[TBL] [Abstract][Full Text] [Related]
8. A comparative study of the bone metabolic response to dried plum supplementation and PTH treatment in adult, osteopenic ovariectomized rat.
Smith BJ; Bu SY; Wang Y; Rendina E; Lim YF; Marlow D; Clarke SL; Cullen DM; Lucas EA
Bone; 2014 Jan; 58():151-9. PubMed ID: 24125756
[TBL] [Abstract][Full Text] [Related]
9. Sequential treatment with basic fibroblast growth factor and PTH is more efficacious than treatment with PTH alone for increasing vertebral bone mass and strength in osteopenic ovariectomized rats.
Iwaniec UT; Mosekilde L; Mitova-Caneva NG; Thomsen JS; Wronski TJ
Endocrinology; 2002 Jul; 143(7):2515-26. PubMed ID: 12072383
[TBL] [Abstract][Full Text] [Related]
10. Abaloparatide, a novel osteoanabolic PTHrP analog, increases cortical and trabecular bone mass and architecture in orchiectomized rats by increasing bone formation without increasing bone resorption.
Chandler H; Lanske B; Varela A; Guillot M; Boyer M; Brown J; Pierce A; Ominsky M; Mitlak B; Baron R; Kostenuik P; Hattersley G
Bone; 2019 Mar; 120():148-155. PubMed ID: 30343166
[TBL] [Abstract][Full Text] [Related]
11. Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys.
Ominsky MS; Stouch B; Schroeder J; Pyrah I; Stolina M; Smith SY; Kostenuik PJ
Bone; 2011 Aug; 49(2):162-73. PubMed ID: 21497676
[TBL] [Abstract][Full Text] [Related]
12. Intermittent minodronic acid treatment with sufficient bone resorption inhibition prevents reduction in bone mass and strength in ovariectomized rats with established osteopenia comparable with daily treatment.
Kimoto A; Tanaka M; Nozaki K; Mori M; Fukushima S; Mori H; Shiroya T; Nakamura T
Bone; 2013 Jul; 55(1):189-97. PubMed ID: 23486179
[TBL] [Abstract][Full Text] [Related]
13. Odanacatib, effects of 16-month treatment and discontinuation of therapy on bone mass, turnover and strength in the ovariectomized rabbit model of osteopenia.
Duong LT; Crawford R; Scott K; Winkelmann CT; Wu G; Szczerba P; Gentile MA
Bone; 2016 Dec; 93():86-96. PubMed ID: 27639811
[TBL] [Abstract][Full Text] [Related]
14. Daily treatment of aged ovariectomized rats with human parathyroid hormone (1-84) for 12 months reverses bone loss and enhances trabecular and cortical bone strength.
Fox J; Miller MA; Newman MK; Metcalfe AF; Turner CH; Recker RR; Smith SY
Calcif Tissue Int; 2006 Oct; 79(4):262-72. PubMed ID: 16969596
[TBL] [Abstract][Full Text] [Related]
15. A new selective estrogen receptor modulator, CHF 4227.01, preserves bone mass and microarchitecture in ovariectomized rats.
Armamento-Villareal R; Sheikh S; Nawaz A; Napoli N; Mueller C; Halstead LR; Brodt MD; Silva MJ; Galbiati E; Caruso PL; Civelli M; Civitelli R
J Bone Miner Res; 2005 Dec; 20(12):2178-88. PubMed ID: 16294271
[TBL] [Abstract][Full Text] [Related]
16. A nonprostanoid EP4 receptor selective prostaglandin E2 agonist restores bone mass and strength in aged, ovariectomized rats.
Ke HZ; Crawford DT; Qi H; Simmons HA; Owen TA; Paralkar VM; Li M; Lu B; Grasser WA; Cameron KO; Lefker BA; DaSilva-Jardine P; Scott DO; Zhang Q; Tian XY; Jee WS; Brown TA; Thompson DD
J Bone Miner Res; 2006 Apr; 21(4):565-75. PubMed ID: 16598377
[TBL] [Abstract][Full Text] [Related]
17. Lycopene treatment against loss of bone mass, microarchitecture and strength in relation to regulatory mechanisms in a postmenopausal osteoporosis model.
Ardawi MM; Badawoud MH; Hassan SM; Rouzi AA; Ardawi JMS; AlNosani NM; Qari MH; Mousa SA
Bone; 2016 Feb; 83():127-140. PubMed ID: 26549245
[TBL] [Abstract][Full Text] [Related]
18. Time course of disassociation of bone formation signals with bone mass and bone strength in sclerostin antibody treated ovariectomized rats.
Ma YL; Hamang M; Lucchesi J; Bivi N; Zeng Q; Adrian MD; Raines SE; Li J; Kuhstoss SA; Obungu V; Bryant HU; Krishnan V
Bone; 2017 Apr; 97():20-28. PubMed ID: 27939957
[TBL] [Abstract][Full Text] [Related]
19. The effect on vertebral bone mass and strength of long term treatment with antiresorptive agents (estrogen and calcitonin), human parathyroid hormone-(1-38), and combination therapy, assessed in aged ovariectomized rats.
Mosekilde L; Danielsen CC; Gasser J
Endocrinology; 1994 May; 134(5):2126-34. PubMed ID: 8156913
[TBL] [Abstract][Full Text] [Related]
20. A comparison of the effects of two anabolic agents (fluoride and PTH) on ash density and bone strength assessed in an osteopenic rat model.
Søgaard CH; Mosekilde L; Thomsen JS; Richards A; McOsker JE
Bone; 1997 May; 20(5):439-49. PubMed ID: 9145241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]